KRAS and non-small cell lung carcinoma: Plangger, et al. [37] showed that BAY-293 can work synergistically with glucose metabolism modulators, cell proliferation inhibitors, several chemotherapeutics and other modulators to exert cytotoxicity to Osimertinib-resistant NSCLC cells with mutated KRAS, and similarly for pancreatic cell lines [38].